O'Donnell EK, et al. - Experts evaluated modified lenalidomide bortezomib dexamethasone (RVD lite) in transplant-ineligible multiple myeloma (MM) patients and was administered over a 35-day cycle focusing on overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Of patients achieved a very good partial response or better, the ORR was 86% and 66 %. Findings suggested 35·1 months to be median PFS and at a median follow-up of 30 months, median OS was not reached. In 62% peripheral neuropathy was seen with only 1 patient experiencing grade 3 symptoms. Results demonstrated well tolerability high effectiveness of RVD lite.